Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma

British Journal of Dermatology

Volumn 164, Issue 5, 2011, Pages 1052-1060

  Fujii, H ^a   Arakawa, A ^a   Kitoh, A ^a   Miyara, M ^b   Kato, M ^a   Kore Eda, S ^a   Sakaguchi, S ^c,d   Miyachi, Y ^a   Tanioka, M ^a   Ono, M ^a,c,d,e  

^a KYOTO UNIVERSITY   (Japan)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c KYOTO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RO ANTIGEN; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; NONREGULATORY T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; CYTOKINES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79955467504     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10199.x     Document Type: Article

References (30)

1. Houghton AN, Gold JS, Blachere NE,. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001; 13: 134-40. (Pubitemid 32176030)
2. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78: 427-32. (Pubitemid 26250527)
3. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
4. Williams KM, Hakim FT, Gress RE,. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007; 19: 318-30. (Pubitemid 350181530)
5. Rosenberg SA, Dudley ME,. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-40.
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16. (Pubitemid 29318842)
7. Shurin MR, Lu L, Kalinski P, et al. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999; 21: 339-59. (Pubitemid 30011443)
8. Kidd P,. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8: 223-46. (Pubitemid 37099886)
9. Gallimore A, Godkin A,. Regulatory T cells and tumour immunity-observations in mice and men. Immunology 2008; 123: 157-63.
10. Zou W,. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
11. Sakaguchi S,. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-62. (Pubitemid 38680433)
12. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112: 4953-60.
13. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39. (Pubitemid 46890865)
14. Jandus C, Bioley G, Speiser DE, et al. Selective accumulation of differentiated FOXP3(+) CD4(+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008; 57: 1795-805.
15. Mizukami Y, Kono K, Kawaguchi Y, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008; 122: 2286-93. (Pubitemid 351542333)
16. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 345-54. (Pubitemid 46523383)
17. Tran DQ, Ramsey H, Shevach EM,. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110: 2983-90. (Pubitemid 350006952)
18. Wang J, Ioan-Facsinay A, Van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-38. (Pubitemid 46128793)
19. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
20. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116: 2423-33. (Pubitemid 44330141)
21. Seddiki N, Santner-Nanan B, Tangye SG, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006; 107: 2830-8.
22. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115: 1953-62. (Pubitemid 40979735)
23. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11. (Pubitemid 32391043)
24. Tatsumi H, Ura H, Ikeda S, et al. Surgical influence on TH1/TH2 balance and monocyte surface antigen expression and its relation to infectious complications. World J Surg 2003; 27: 522-8. (Pubitemid 36961119)
25. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202: 885-91. (Pubitemid 41396888)
26. Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66: 4488-95.
27. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9. (Pubitemid 39273735)
28. Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 1064-71. (Pubitemid 43800721)
29. Ono M, Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446: 685-9. (Pubitemid 46606883)
30. Koch MA, Tucker-Heard G, Perdue NR, et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10: 595-602.